Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Research & Development (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Research & Development for 4 consecutive years, with $14.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 20.97% to $14.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $52.3 million, a 29.72% increase, with the full-year FY2024 number at $42.8 million, up 26.56% from a year prior.
  • Research & Development was $14.0 million for Q3 2025 at Orchestra BioMed Holdings, up from $13.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $14.0 million in Q3 2025 to a low of $3.5 million in Q1 2022.
  • A 4-year average of $9.3 million and a median of $8.6 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 137.59% in 2023, then grew 10.39% in 2024.
  • Orchestra BioMed Holdings' Research & Development stood at $7.5 million in 2022, then increased by 12.83% to $8.5 million in 2023, then increased by 28.9% to $11.0 million in 2024, then grew by 27.86% to $14.0 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Research & Development are $14.0 million (Q3 2025), $13.9 million (Q2 2025), and $13.5 million (Q1 2025).